Background竊�There are very limited data regarding role of statins in managing acute non-ST-segment elevation myocardial infarction (NSTEMI), especially in drug-eluting stent (DES) era.Method: The study population consisted of 2425 consecutive acute NSTEMI patients (pts) enrolled in the Korea Acute Myocardial Infarction Registry (KAMIR) study from November 2005 to April 2008. Statin administration, types and doses were depending on the physician���s discretion and 1805 pts were received from the presentation time. We investigated the clinical outcomes with propensity score(PS) adjustment between 1805 statin-naïve pts and those without statin treatment (n=620) up to 12 months.Results: The baseline characteristics are similar between the two groups, except less diabetes pts in Statins group (31.0% vs 35.5%, p=0.038). Mortality, repeat PCI predominantly derived by less non-TVR, recurrent AMI and total major adverse cardiac events (MACE) were significantly lower in the statin group (Table). Statin administration was associated with less incidence of MACE at 12 months (ORunadjusted:0.487, 95% CI: 0.377-0.628, P<0.01; ORadjusted by ps:0.599, 95% CI: 0.445-0.806, P=0.001).Conclusion: Routine administration of Statins in acute NSTEMI pts regardless of the revascularization strategy showed better 12-month clinical outcomes compared with those of NSTEMI pts without statin therapy.